MedPath

Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma

Not Applicable
Completed
Conditions
Lymphoma
Interventions
Behavioral: 3RP-Lymphoma
Registration Number
NCT03212261
Lead Sponsor
Massachusetts General Hospital
Brief Summary

The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of individuals who have completed treatment for lymphoma (3RP-Lymphoma).

Detailed Description

The Relaxation Response Resiliency Program, or 3RP, was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine. The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being.

The 3RP has not yet been carried out with individuals who have recently completed treatment for lymphoma. As such, the investigators have adapted the standard 3RP program to target the specific needs of lymphoma patients who are transitioning off active treatment. The investigators are conducting this study to see if the adapted program, the 3RP-Lymphoma, is effective at reducing stress and stress-related symptoms for people who have completed treatment for lymphoma within the past two years. To develop the 3RP-Lymphoma, the investigators conducted interviews with patients who had recently completed treatment to learn about their experiences and their preferences for topics they would want to include in a program tailored to their specific needs. The current phase of the feasibility study will examine if the adapted program is feasible, acceptable, and helps promote stress management among lymphoma survivors who are in the early stages of completing cancer treatment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
37
Inclusion Criteria
  • Aged 18-64
  • Within 2 years post-treatment completion for lymphoma
  • English speaking
  • Able and willing to provide informed consent
  • Cancer treatment or follow-up for lymphoma at the MGH Cancer Center
Exclusion Criteria
  • Unwilling or unable to participate in the study
  • Unable to speak or read English
  • Is medically, psychiatrically, or otherwise unable to participate (as determined by a physician or study PI)
  • Unwilling or unable to participate in group 3RP sessions delivered via the Partners Telehealth videoconferencing software
  • Participation in qualitative interview during Phase 1 (DF/HCC 16-396)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
3RP-Lymphoma3RP-Lymphoma-An adapted version of the 3RP (3RP-Lymphoma) for lymphoma survivors recently completing cancer treatment. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.
Primary Outcome Measures
NameTimeMethod
Program Feasibility: Number of Participants Who Completed at Least 75% of the Treatment Sessions1 month after completing the 3RP-Lymphoma program

The investigators will evaluate program feasibility by examining rates of treatment completion. Participants who complete at least 75% of the treatment sessions will be identified as treatment completers.

Number of Participants Who Found the 3RP Program Acceptable1 month after completing the 3RP-Lymphoma program

Acceptability will be assessed at the one-month follow up data collection period with five questions on the 3RP acceptability questionnaire rated on a 4-point Likert scale (1=not at all to 4=very much); higher scores mean higher levels of acceptability.

Secondary Outcome Measures
NameTimeMethod
Number of Participants Who Were Eligible to Provide and Provided Hair Cortisol Samples1 month after completing the 3RP-Lymphoma program

The investigators will explore the feasibility and acceptability of collecting hair samples to examine levels of cortisol, a stress biomarker.

Trial Locations

Locations (1)

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath